UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1093-12
Program Prior Authorization/Notification
Medication Signifor® (pasireotide diaspartate)
P&T Approval Date 2/2013, 5/2013, 11/2013, 11/2014, 11/2015, 9/2016, 9/2017, 9/2018,
9/2019, 9/2020, 9/2021, 10/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Signifor (pasireotide diaspartate) is a somatostatin analog indicated for the treatment of adult
patients with Cushing’s disease for whom pituitary surgery is not an option or has not been
curative.
2. Coverage Criteriaa:
A. Initial Authorization
1. Signifor will be approved based on both of the following criteria:
a. Diagnosis of endogenous Cushing’s disease (i.e., hypercortisolism is not a result of
chronic administration of high dose glucocorticoids)
-AND-
b. One of the following:
(1) Pituitary surgery has not been curative for the patient
(2) Patient is not a candidate for pituitary surgery
Authorization will be issued for 12 months.
B. Reauthorization
1. Signifor will be approved based on the following criterion:
a. Documentation of positive clinical response to Signifor therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Signifor [package insert]. Bridgewater, NJ: Recordati Rare Diseases, Inc.; July 2024.
Program Prior Authorization/Notification - Signifor (pasireotide diaspartate)
Notification
Change Control
2/2013 New program.
5/2013 Initial authorization period revised based upon consultant feedback.
11/2013 Formatting update. Removal of dose information in Background
Section.
11/2014 Annual review with no change to coverage.
11/2015 Annual review. Updated background info. Changed authorization
period from 3 months to 6 months. Updated references.
9/2016 Annual review. No change to coverage criteria.
9/2017 Annual review with no changes to coverage criteria.
9/2018 Annual review with no changes to coverage criteria. Updated
reference.
9/2019 Annual review with no changes to coverage criteria. Updated
reference.
9/2020 Annual review with no changes to coverage criteria. Updated
reference.
9/2021 Annual review with no changes to coverage criteria. Updated
reference.
10/2022 Annual review with no changes to coverage criteria. Added state
mandate footnote.
10/2023 Annual review with no changes to coverage criteria.
10/2024 Annual review. Updated initial authorization duration to 12 months and
updated reference.
© 2024 UnitedHealthcare Services, Inc.
2